Takeda Y - Search Results

1

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer.

Masuhiro K, Tamiya M, Fujimoto K, Koyama S, Naito Y, Osa A, Hirai T, Suzuki H, Okamoto N, Shiroyama T, Nishino K, Adachi Y, Nii T, Kinugasa-Katayama Y, Kajihara A, Morita T, Imoto S, Uematsu S, Irie T, Okuzaki D, Aoshi T, Takeda Y, Kumagai T, Hirashima T, Kumanogoh A. Masuhiro K, et al. Among authors: takeda y. JCI Insight. 2022 May 9;7(9):e157915. doi: 10.1172/jci.insight.157915. JCI Insight. 2022. PMID: 35389889 Free PMC article.

2

Construction and analysis of new vector systems with improved interleukin-18 secretion in a xenogeneic human tumor model.

Goto H, Osaki T, Nishino K, Tachibana I, Takeda Y, Yoneda T, Funakoshi T, Kimura H, Hayashi S, Tahara H. Goto H, et al. Among authors: takeda y. J Immunother. 2002 Mar-Apr;25 Suppl 1:S35-41. doi: 10.1097/00002371-200203001-00006. J Immunother. 2002. PMID: 12048349

3

Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer.

Funakoshi T, Tachibana I, Hoshida Y, Kimura H, Takeda Y, Kijima T, Nishino K, Goto H, Yoneda T, Kumagai T, Osaki T, Hayashi S, Aozasa K, Kawase I. Funakoshi T, et al. Among authors: takeda y. Oncogene. 2003 Feb 6;22(5):674-87. doi: 10.1038/sj.onc.1206106. Oncogene. 2003. PMID: 12569360

4

The extracellular domain of p185(c-neu) induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo.

Yoneda T, Kumagai T, Nagatomo I, Furukawa M, Yamane H, Hoshino S, Mori M, Takeda Y, Horai T, Nishida S, Watanabe D, Kijima T, Yoshida M, Osaki T, Tachibana I, Greene MI, Kawase I. Yoneda T, et al. Among authors: takeda y. DNA Cell Biol. 2006 Sep;25(9):530-40. doi: 10.1089/dna.2006.25.530. DNA Cell Biol. 2006. PMID: 16989576

5

Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells.

Saito Y, Tachibana I, Takeda Y, Yamane H, He P, Suzuki M, Minami S, Kijima T, Yoshida M, Kumagai T, Osaki T, Kawase I. Saito Y, et al. Among authors: takeda y. Cancer Res. 2006 Oct 1;66(19):9557-65. doi: 10.1158/0008-5472.CAN-06-1131. Cancer Res. 2006. PMID: 17018612

6

Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.

Kijima T, Suzuki M, Ueda K, Minami S, Takeda Y, Goya S, Matsuoka H, Kumagai T, Yoshida M, Osaki T, Tachibana I, Yokota S, Kawase I. Kijima T, et al. Among authors: takeda y. Oncol Res. 2007;16(10):489-95. doi: 10.3727/096504007783338313. Oncol Res. 2007. PMID: 18196873

7

Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation.

Suzuki M, Tachibana I, Takeda Y, He P, Minami S, Iwasaki T, Kida H, Goya S, Kijima T, Yoshida M, Kumagai T, Osaki T, Kawase I. Suzuki M, et al. Among authors: takeda y. J Immunol. 2009 May 15;182(10):6485-93. doi: 10.4049/jimmunol.0802797. J Immunol. 2009. PMID: 19414803

8

Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer.

Kohmo S, Kijima T, Otani Y, Mori M, Minami T, Takahashi R, Nagatomo I, Takeda Y, Kida H, Goya S, Yoshida M, Kumagai T, Tachibana I, Yokota S, Kawase I. Kohmo S, et al. Among authors: takeda y. Cancer Res. 2010 Oct 15;70(20):8025-35. doi: 10.1158/0008-5472.CAN-10-0996. Epub 2010 Oct 12. Cancer Res. 2010. PMID: 20940407

9

Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.

Tetsumoto S, Osa A, Kijima T, Minami T, Hirata H, Takahashi R, Kuhara H, Nagatomo I, Takeda Y, Kida H, Goya S, Tachibana I, Kawase I. Tetsumoto S, et al. Among authors: takeda y. Int J Clin Oncol. 2012 Apr;17(2):155-9. doi: 10.1007/s10147-011-0256-9. Epub 2011 May 19. Int J Clin Oncol. 2012. PMID: 21594553

10

Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.

Takahashi R, Hirata H, Tachibana I, Shimosegawa E, Inoue A, Nagatomo I, Takeda Y, Kida H, Goya S, Kijima T, Yoshida M, Kumagai T, Kumanogoh A, Okumura M, Hatazawa J, Kawase I. Takahashi R, et al. Among authors: takeda y. Clin Cancer Res. 2012 Jan 1;18(1):220-8. doi: 10.1158/1078-0432.CCR-11-0868. Epub 2011 Oct 21. Clin Cancer Res. 2012. PMID: 22019513

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,542 results

Search Page